Alternating Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma: A Phase II Study of Alternating Sunitinib and Temsirolimus
In the past 5 years, treatment for metastatic Renal Cell Carcinoma (mRCC) has focused on
agents directed at blocking tumor and vascular growth pathways. Sunitinib blocks the
vascular endothelial growth factor receptor (VEGFr) and temsirolimus is an inhibitor of
mammalian target of rapamycin (mTOR). Both sunitinib and temsirolimus are FDA approved
agents for mRCC. When agents like these are given together, the toxicity increases but they
can be given safely, at full doses, sequentially. We hypothesize that alternating these
agents will double the progression free survival (PFS) of the agents when given
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.